Septerna Reports $21.5 Million Revenue for Q3 2025, Achieves Net Income of $8.2 Million

Septerna, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenue of $21.5 million for the third quarter, a substantial increase from just $176,000 in the same period last year. For the nine months ended September 30, 2025, total revenue reached $21.8 million, compared to $863,000 in the prior year. This growth is attributed primarily to a collaboration agreement with Novo Nordisk A/S, which included a one-time upfront payment of $195 million, and a milestone payment of $12.5 million from Vertex Pharmaceuticals.

Operating expenses for the third quarter were $18.9 million, down from $22.7 million in the same quarter of 2024, largely due to a gain on the sale of a non-financial asset. Research and development expenses increased to $24.3 million from $17.8 million year-over-year, reflecting the company's ongoing investment in its clinical and preclinical programs. General and administrative expenses also rose to $7.1 million from $4.9 million, driven by higher employee-related costs and operational expenses associated with being a public company. The company reported a net income of $8.2 million for the quarter, a significant turnaround from a net loss of $20.5 million in the same period last year.

In terms of operational metrics, Septerna's total assets increased to $606.7 million as of September 30, 2025, up from $456.6 million at the end of 2024. The company’s cash and cash equivalents stood at $320 million, bolstered by the proceeds from its IPO in October 2024, which raised $302.8 million. The company’s accumulated deficit reached $156.5 million, reflecting its ongoing investment in research and development without any product sales to date.

Strategically, Septerna is advancing multiple programs, including the SEP-479 PTH1R agonist and SEP-631 MRGPRX2 negative allosteric modulator, with plans to initiate a Phase 1 clinical trial for SEP-479 in the first half of 2026. The company is also focused on expanding its pipeline through its proprietary Native Complex Platform, which aims to enhance GPCR drug discovery. Looking ahead, Septerna anticipates continued investment in its research and development efforts, with expectations of increased expenditures as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company believes its current cash reserves will be sufficient to fund operations for at least the next 12 months.